First-in-Human Adjunctive Bacteriophage Therapy for Malakoplakia.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 42578807.
- Also identified by DOI 10.1093/cid/ciag446.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We report the first use of adjunctive bacteriophage therapy for Escherichia coli related malakoplakia in a kidney transplant recipient with progressive disease. Adjunctive CRISPR-enhanced phage cocktail SNIPR001 combined with prolonged antibiotics, ascorbic acid, and bethanechol was associated with cutaneous lesion resolution and sustained radiographic regression without phage-related adverse events.